Teva Pharmaceutical Industries Limited [NYSE: TEVA] closed the trading session at $8.81 on 07/23/21. The day’s price range saw the stock hit a low of $8.77, while the highest price level was $8.93. The company report on July 21, 2021 that Teva Announces Changes to Executive Management Team.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced changes to its leadership team. Brendan O’Grady, Executive Vice President, North America Commercial, will leave Teva to pursue a career opportunity outside of the pharmaceutical industry, and Sven Dethlefs, who currently serves as Teva’s Executive Vice President, Global Marketing and Portfolio and International Markets Commercial has been appointed the new head of North America Commercial.
In addition, Teva announced the following changes to the Executive Management team:.
The stocks have a year to date performance of -8.70 percent and weekly performance of 2.32 percent. The stock has been moved at -29.80 percent over the last six months. The stock has performed -13.63 percent around the most recent 30 days and changed -13.96 percent over the most recent 3-months.
If compared to the average trading volume of 8.69M shares, TEVA reached to a volume of 8082406 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Teva Pharmaceutical Industries Limited [TEVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $11.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Teva Pharmaceutical Industries Limited shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 04, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Sector Perform. The new note on the price target was released on April 07, 2021, representing the official price target for Teva Pharmaceutical Industries Limited stock. On August 06, 2020, analysts increased their price target for TEVA shares from 10 to 13.
The Average True Range (ATR) for Teva Pharmaceutical Industries Limited is set at 0.27, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 0.61. The Price to Book ratio for the last quarter was 0.97, with the Price to Cash per share for the same quarter was set at 1.55.
TEVA stock trade performance evaluation
Teva Pharmaceutical Industries Limited [TEVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.32. With this latest performance, TEVA shares dropped by -13.63% in over the last four-week period, additionally sinking by -29.80% over the last 6 months – not to mention a drop of -24.96% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 36.23, with the RSI for the last a single of trading hit 37.40, and the three-weeks RSI is set at 37.14 for Teva Pharmaceutical Industries Limited [TEVA]. The present Moving Average for the last 50 days of trading for this stock 10.09, while it was recorded at 8.78 for the last single week of trading, and 10.44 for the last 200 days.
Teva Pharmaceutical Industries Limited [TEVA]: An insightful look at the core fundamentals
Teva Pharmaceutical Industries Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.
Earnings per share (EPS) analysis for Teva Pharmaceutical Industries Limited [TEVA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva Pharmaceutical Industries Limited go to 5.77%.
Teva Pharmaceutical Industries Limited [TEVA]: Insider Ownership positions
There are presently around $5,048 million, or 52.30% of TEVA stock, in the hands of institutional investors. The top three institutional holders of TEVA stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 128,693,223, which is approximately -1.112% of the company’s market cap and around 1.05% of the total institutional ownership; CAPITAL WORLD INVESTORS, holding 53,020,773 shares of the stock with an approximate value of $467.11 million in TEVA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $376.97 million in TEVA stock with ownership of nearly 0% of the company’s market capitalization.
178 institutional holders increased their position in Teva Pharmaceutical Industries Limited [NYSE:TEVA] by around 41,128,709 shares. Additionally, 180 investors decreased positions by around 47,100,511 shares, while 130 investors held positions by with 484,716,353 shares. The mentioned changes placed institutional holdings at 572,945,573 shares, according to the latest SEC report filing. TEVA stock had 55 new institutional investments in for a total of 4,254,766 shares, while 46 institutional investors sold positions of 7,264,859 shares during the same period.